Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 3 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 08 Dec 2016

Icotinib improves progression-free survival (PFS) and objective response rate (ORR) vs whole-brain irradiation (WBI) plus chemotherapy in Chinese patients with non-small-cell lung cancer (NSCLC) and brain metastases, according to a phase III study presented recently at the 17th World Conference on Lung Cancer (WCLC).

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).

Ramucirumab plus emibetuzumab shows favourable antitumour efficacy in advanced cancer

27 Sep 2019

Treatment with ramucirumab plus emibetuzumab is safe and exerts cytostatic antitumour activity, especially in patients with advanced hepatocellular carcinoma (HCC), according to the results of a phase IB/II trial.

The trial involved six patients in the dose-escalation phase (IB; three at each of the two dose levels) and 91 patients in the four tumour-specific expansion cohorts: gastric or gastroesophageal junction adenocarcinoma (GEJ; n=16), HCC (n=45), renal cell carcinoma (RCC; n=15) and nonsmall cell lung cancer (n=15). Emibetuzumab was administered at either 750 or 2,000 mg flat dosing, while ramucirumab was given at 8 mg/kg every 2 weeks.

Primary objectives were to determine the recommended phase II dose and to evaluate antitumour activity. Secondary objectives included safety, pharmacokinetics and immunogenicity. Tumoural MET expression was explored by immunohistochemistry (IHC).

Emibetuzumab exposures were consistent in previous studies with no apparent drug–drug interactions. Five partial responses (5.2 percent) occurred across all tumour types. Antitumour activity was greatest in HCC, with an overall response rate of 6.7 percent, disease control rate of 60 percent, and progression free survival (PFS) of 5.42 months (95 percent CI, 1.64–8.12).

Of note, PFS was threefold higher in HCC with high vs low MET expression (8.1 vs 2.8 months).

There were no dose-limiting toxicities documented. Common adverse events were mostly mild or moderate in severity and included fatigue (36.1 percent), peripheral oedema (28.9 percent) and nausea (14.4 percent).

The findings indicate that MET expression may help aid in selecting patients who will benefit most from this combination treatment in select tumour types, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 3 days ago
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Christina Lau, 08 Dec 2016

Icotinib improves progression-free survival (PFS) and objective response rate (ORR) vs whole-brain irradiation (WBI) plus chemotherapy in Chinese patients with non-small-cell lung cancer (NSCLC) and brain metastases, according to a phase III study presented recently at the 17th World Conference on Lung Cancer (WCLC).

Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).